1. Home
  2. WYY vs IBIO Comparison

WYY vs IBIO Comparison

Compare WYY & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

N/A

Current Price

$5.91

Market Cap

62.9M

Sector

Technology

ML Signal

N/A

IBIO

iBio Inc.

N/A

Current Price

$0.72

Market Cap

52.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WYY
IBIO
Founded
1991
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.9M
52.8M
IPO Year
2005
2009

Fundamental Metrics

Financial Performance
Metric
WYY
IBIO
Price
$5.91
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $5.69
AVG Volume (30 Days)
122.0K
★ 470.8K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.71
EPS
★ N/A
N/A
Revenue
★ $150,545,364.00
N/A
Revenue This Year
$12.26
N/A
Revenue Next Year
$25.66
N/A
P/E Ratio
$617.00
★ N/A
Revenue Growth
★ 5.59
N/A
52 Week Low
$3.96
$0.69
52 Week High
$24.30
$3.82

Technical Indicators

Market Signals
Indicator
WYY
IBIO
Relative Strength Index (RSI) 34.96 37.52
Support Level $5.60 $0.71
Resistance Level $7.74 $0.85
Average True Range (ATR) 0.42 0.06
MACD -0.01 0.01
Stochastic Oscillator 8.33 15.62

Price Performance

Historical Comparison
WYY
IBIO

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About IBIO iBio Inc.

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Share on Social Networks: